Abstract | BACKGROUND: STUDY DESIGN AND METHODS: Two patient cohorts were studied. In Cohort 1, the prevalence of hypercalcemia in 1606 sarcoidosis patients seen during a six year period was analyzed along with treatment and outcome. Cohort 2 consisted of 261 sarcoidosis patients with measured 25-(OH) vitamin D3 and 1,25-(OH) vitamin D3 levels. In forty patients, serial levels of 25-(OH) vitamin D3 and 1,25-(OH) vitamin D3 were measured at least three months apart without change in therapy. RESULTS: SAHC was identified in 97 of 1606 (6%) of patients studied and additional nine (0.6%) patients had primary hyperparathyroidism. Post treatment follow up was available in 86 SAHC patients. Hypercalcemia improved in >90% of patients, including eight patients treated solely with vitamin D supplement withdrawal. Renal insufficiency, documented in 41 (42%) of SAHC patients, improved with hypercalcemia treatment. In 80% of Cohort 2 patients low 25-(OH) vitamin D3 levels were measured with only one patient having a low 1,25( OH)2 vitamin D3 level. Elevated 1,25( OH)2 vitamin D3 levels, which were measured in 11% of patients, were higher for those with a history of hypercalcemia. CONCLUSION:
|
Authors | R P Baughman, J Janovcik, M Ray, N Sweiss, E E Lower |
Journal | Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG
(Sarcoidosis Vasc Diffuse Lung Dis)
Vol. 30
Issue 2
Pg. 113-20
(Aug 01 2013)
ISSN: 2532-179X [Electronic] Italy |
PMID | 24071882
(Publication Type: Journal Article)
|
Chemical References |
- Calcium, Dietary
- Vitamin D
- Calcium
|
Topics |
- Calcium
(blood)
- Calcium, Dietary
- Humans
- Hypercalcemia
(blood)
- Sarcoidosis
- Vitamin D
|